phate and urea concentrations, urinary flow rate, urinary Na + , phosphate and glucose excretion, blood pressure and proteinuria. Conclusions: GA treatment decreases blood pressure and proteinuria in diabetic mice and may thus prove beneficial in diabetic nephropathy.
Effects of Gum Arabic (Acacia senegal) on Renal Function in Diabetic Mice
countries GA is widely used in the treatment of patients with chronic kidney disease and end-stage renal disease [6] . GA was found to increase fecal nitrogen excretion [7] , to decrease production of free oxygen radicals [6] , and to modestly counteract renal injury following acute gentamicin nephrotoxicity in rats [8] . In healthy mice, GA treatment has been shown to increase creatinine clearance and renal ADH excretion as well as intestinal and renal excretion of Mg 2+ and Ca 2+ [9] . It has also been shown to lower plasma concentration of 1,25(OH) 2 D 3 as well as urinary P i and Na + excretion [9] . A major cause of end-stage renal disease is diabetic nephropathy [10] . The present study thus explored the effects of GA on renal function in diabetic mice. To this end, metabolic cage experiments were performed on heterozygous Akita (akita +/-) mice, which develop spontaneous diabetes due to the gradual destruction of pancreatic ␤ -cells [11] . It is shown that GA treatment of those mice indeed influences renal function. Most importantly, GA treatment decreased proteinuria, an important parameter for the progression of renal disease [12] [13] [14] [15] [16] [17] [18] .
Methods
Gum Arabic GA in powder form was provided as a generous gift from Dar Savanna Ltd., Khartoum, Sudan (www.ssgums.com). The fully natural extract powder with a particle size smaller than 210 m was produced mechanically from wildly grown A. senegal trees. The quality conforms to the food and pharmaceutical requirements of the Food and Agriculture Organization of the United Nations (FAO), British pharmacopoeia (BP), United States pharmacopoeia (USP) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA).
Optical rotation was determined on a Perkin Elmer model 341 polarimeter. GA was dissolved in water and measured at 20 ° C to obtain a value of -28°. 1 H HR/MAS NMR spectra of GA was recorded on a Bruker ARX 400-MHz spectrometer at a spinning rate of 4 kHz in a 4-mm double-bearing ZrO 2 rotor. The spectrometer was equipped with a deuterium lock setup, which was set on the resonance frequency of D 2 O. The 90° pulse length was set to 10.5 s. Spectra were recorded at 313 K and multiplied by an exponential line broadening function of lb = 0.5 Hz prior to Fourier transformation. Spectrum processing was performed using Bruker TOPSPIN 2.0 software. Assignment of the GA proton COSY HR/MAS NMR spectrum was obtained for a number of cross-peaks starting from the anomeric protons. Figure 1 displays the spectrum with the labeled cross-peaks as reported previously [19] . The obtained data is in accordance with JECFA specifications and provides valuable information on the studied sample [20, 21] .
Animals
Experiments were carried out on heterozygous akita +/-mice (age: 3-8 months) which spontaneously develop diabetes. Before including the mice in the study the diabetic phenotype was assured by the determination of plasma glucose concentrations. A glucose concentration above 200 mg/dl was considered as diabetic. The animals were housed under controlled environmental conditions (22-24 ° C, 50-70% humidity and a 12-hour light/dark cycle). Throughout the study the mice had free access to standard pelleted food (Altromin, Lage, Germany) and tap water or GA solution as indicated. All animal experiments were conducted according to the guidelines of the American Physiological Society and the German law for the care and welfare of animals and were approved by local authorities.
GA Treatment
GA was administered by the addition of 10% (w/w) GA to the tap drinking water (100 g/l). The preparations were refreshed every 3 days during the treatment. The effects of GA administration were investigated before treatment with GA, after 1 week and after 2 weeks of GA treatment. The intake corresponded to a dose of approximately 20 g/kg body weight/day.
Collection of Urine
For the evaluation of renal excretion as well as daily food and fluid intake, the mice were placed individually in metabolic cages (Techniplast, Hohenpeissenberg, Germany) for 24 h and urine was collected with free access to fluid as well as standard diet. Collections were performed at baseline with tap water, and with GAcontaining drinking water for 1 or 2 weeks. The inner wall of the metabolic cages was siliconized, and urine was collected under water-saturated oil.
Determination of Plasma and Urinary Concentrations
To obtain blood specimens, the animals were lightly anesthetized with diethylether (Roth, Karlsruhe, Germany), and approximately 130 l of blood was withdrawn into heparinized capillaries by puncturing the retro-orbital plexus.
The plasma and urinary concentrations of Na + , K + and Ca 2+ were measured by flame photometry (AFM 5051, Eppendorf, Germany) or by a photometric method according to the manufacturer's instructions (dri-chem clinical chemistry analyzer FUJI FDC 3500i, Sysmex, Norsted, Germany). Urinary creatinine concentrations were measured using a kinetic Jaffé method. The plasma and urinary phosphate concentrations were measured photometrically using kits from Roche Diagnostics (Mannheim, Germany). Plasma urea was measured by an enzymatic method (Lehmann, Berlin, Germany). The blood glucose concentration was determined utilizing a glucometer (Accutrend, Roche, Mannheim, Germany). The urinary glucose concentration was determined utilizing a commercial enzymatic kit (Gluco-quant, Roche Diagnostics, Mannheim, Germany). Plasma aldosterone concentration was measured using an RIA kit (Demeditec, Kiel, Germany).
Urinary albumin was measured fluorometrically using the albumin-sensitive dye albumin blue 580 at 595-nm excitation and 642-nm emission on a Wallac counter (Victor 1420) according to the manufacturer's instructions (microfluoral, Progen, Heidelberg, Germany). Standard curves were generated with mouse albumin (Sigma, Schnelldorf, Germany), and measurements were performed within the linear range (0-156 mg/l).
Blood Pressure Measurements
Systolic arterial blood pressure was determined by the tail-cuff method (IITC, Model 179, Woodland Hills, Calif., USA). Application of this method requires certain precautions to reduce the stress of the animals, including appropriate training of the mice over multiple days and adequate prewarming to dilate the tail artery. The animals were placed in a heated chamber at an ambient temperature of 30-32 ° C. Animal blood pressure traces were recorded in one session until the deviation of a minimum of 5 traces was lower than 5 mm Hg. The readings from 3 days were then averaged to obtain a mean blood pressure under the respective treatment. All recordings and data analysis were done using a computerized data acquisition system and software (PowerLab 400 and Chart 5, both AdInstruments, Colorado Springs, Colo., USA). All measurements were performed by the same person during a defined time.
Statistical Analysis
Data are provided as arithmetic means 8 SEM, and n represents the number of independent experiments. Data were tested for significance using the paired two-tailed Student t test when two-sample means were tested. p ! 0.05 was considered statistically significant.
Results
As described earlier [11] , heterozygous akita +/-mice developed marked and statistically significant hyperglycemia ( fig. 2 ) . Treatment of the akita +/-mice with GA tended to slightly decrease the plasma glucose concentration, an effect, however, not reaching statistical significance. The treatment significantly reduced the urinary glucose excretion ( fig. 2 ) .
Within the observed treatment period of up to 2 weeks, GA did not significantly modify the body weight of the akita +/-mice ( fig. 3 ) despite a significant decrease of food intake following GA treatment ( fig. 3 ) . Similarly, fluid intake and as a result urinary output were decreased following GA treatment of the akita +/-mice ( fig. 3 ). The decrease of glucosuria and urinary flow rate of the akita +/-mice was paralleled by a significantly decreased urinary Na + excretion ( fig. 4 ; table 1 ). Urinary K + excretion tended to decrease following GA treatment, an effect, however, not reaching statistical significance ( fig. 4 ; table 1 ). Neither plasma Na + concentration nor plasma K concentration of the akita +/-mice were significantly modified by the GA treatment ( fig. 4 ) .
GA treatment of akita +/-mice significantly increased the urinary excretion of Ca 2+ ( fig. 5 ). Plasma Ca 2+ concentration tended to increase following GA treatment, an effect, however, not reaching statistical significance ( fig. 5 ). GA treatment of akita +/-mice was followed by a profound and significant decrease of plasma phosphate concentration paralleled by a significant decrease of urinary phosphate excretion ( fig. 5 ) .
As illustrated in figure 6 , the diabetic akita +/-mice developed albuminuria. Surprisingly, the albuminuria was significantly decreased by GA treatment. Urinary creatinine excretion remained constant during GA treatment ( fig. 6 ).
Plasma urea concentration and fractional urea excretion decreased in GA-treated akita +/-mice ( fig. 7 ; table 1 ). Plasma aldosterone concentration was not significantly modified by GA treatment ( fig. 7 ) .
As shown in figure 8 , GA treatment was followed by a marked and significant decrease of arterial blood pressure.
In wild-type mice, GA treatment significantly reduced urinary Na + excretion ( table 2 ) . 
Discussion
The present study reveals novel effects of GA. In diabetic heterozygous akita +/-mice, GA treatment decreased glucosuria without appreciably influencing the plasma glucose concentration. Possibly, GA increased renal tubular glucose transport. Despite the decrease of urinary glucose loss, the plasma glucose concentration was not significantly modified by GA treatment. Presumably, the decreased food intake compensated for the decreased urinary glucose loss and thus, neither plasma glucose concentration nor body weight was significantly modified by GA treatment.
The reduced glucosuria might have contributed to the decrease of urinary volume and urinary Na + , K + and urea excretion. Glucosuria imposes an osmotic diuresis with subsequent renal loss of electrolytes [22] . Moreover, GA treatment increases the release of ADH [9] , which may have contributed to the decreased fluid, Na + and urea excretion.
The antinatriuresis was paralleled by calciuria, which is presumably secondary to enhanced Ca 2+ intake. GA is rich in Ca 2+ salts ( table 3 ) [3] . Accordingly, a calciuric effect of GA treatment has been reported earlier in healthy mice [9] . In this earlier study the increased uptake of calcium was followed by suppression of the secretion of the biologically active 1,25(OH) 2 D 3 and a tendency of PTH plasma concentration to similarly decrease [9] . The decrease of plasma PTH and 1,25(OH) 2 D 3 concentrations is expected to reduce renal tubular Ca 2+ reabsorption and thus presumably contributes to or even accounts for the calciuria [23, 24] .
A decrease of the plasma 1,25(OH) 2 D 3 concentration is expected to decrease intestinal phosphate absorption, which may account for the decline of plasma phosphate concentration. The hypophosphatemia is in turn expected to result in antiphosphaturia, which has indeed been observed in healthy [9] and diabetic mice. The antiphosphaturia would be further fostered by reduced PTH plasma levels [25] .
The most striking observation was the marked decrease of albuminuria following GA treatment. The decrease of albuminuria could have been due to a decrease of blood pressure. In an earlier study [9] , we did not observe a significant effect of GA treatment on plasma aldosterone concentration or blood pressure of healthy mice. In the present study on diabetic mice, however, GA did significantly decrease blood pressure. Moreover, an antihypertensive effect of GA has been demonstrated earlier in humans [26] . The effect of GA on blood pressure could at least in part be acid and sodium D , L -3-hydroxybutyrate have in turn been shown to increase the glomerular filtration rate and renal blood flow in humans [31] . It is tempting to speculate that the enhanced butyrate formation influences glomerular function during GA treatment. GA is used in Middle Eastern countries for the treatment of patients with chronic and end-stage kidney disease [6] . The present data indeed disclose some effects of GA treatment, which may be beneficial for patients with renal disease. First, the decrease of proteinuria is expected to delay the progression of renal disease [12] . Second, the decrease of plasma phosphate concentration increases the plasma concentration of ionized Ca 2+ and thus counteracts hyperparathyroidism, a major pathophysiological parameter in advanced renal disease [32] [33] [34] . Third, an increase in creatinine clearance, as has been observed earlier [9] , counteracts the decline of renal excretory function. Our data are thus indeed suggestive of a favorable influence of GA treatment on renal function in diabetic individuals. It should, however, be pointed out that the phenotype of the akita +/-mice is not that of fully developed diabetic nephropathy. Rather, the renal function reflects that of early diabetes.
At least in theory, the composition and chemical property and thus the biological effects of GA may vary. It remains to be shown whether other preparations of GA are similarly effective.
In conclusion, this present study reveals several effects of GA treatment, which may delay the progression to renal failure in diabetes. Most importantly, GA treatment decreases proteinuria, lowers plasma phosphate concentration and increases the glomerular filtration rate. due to enhanced Ca 2+ intake, which has been shown to lower blood pressure, an effect attributed in part to stimulation of the Ca 2+ -sensing receptor with subsequent inhibition of the Na
-cotransport in the thick ascending limb [27] or triggering of vasodilation [28] .
The present study does not rule out antiproteinuric effects of GA treatment involving additional mechanisms unrelated to blood pressure. GA treatment was further associated with an increased creatinine clearance [9] . The mechanisms involved in the influence of GA treatment on glomerular function remain elusive. The fermentation of GA by intestinal bacteria leads to the formation of several degradation products including short-chain fatty acids [29] . Accordingly, GA treatment has previously been shown to enhance the serum butyrate concentration in healthy subjects [30] . Infusion of D , L -3-hydroxybutyric 
